Bellicum Pharmaceuticals Announces Departure of Chief Financial Officer
July 16 2018 - 4:25PM
Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in
developing novel, controllable cellular immunotherapies for cancers
and orphan inherited blood disorders, today announced that Alan
Musso, Chief Financial Officer, will be leaving the Company
effective August 31, 2018. Rosemary Williams, Bellicum’s Vice
President of Finance and Controller, will serve as the Company’s
interim principal accounting officer. “On behalf of the entire
company and our Board of Directors, I want to thank Alan for his
dedication and significant contributions and wish him well as he
moves on to a new opportunity,” stated Bellicum’s President &
CEO Rick Fair. “With the recent financing, we are well capitalized
to continue executing on our business plan and look forward to
upcoming readouts on our clinical programs.”
Bellicum has initiated a search process to appoint a new CFO and
Mr. Musso will provide support to the Company in a consultancy role
during the transition. About Bellicum
Pharmaceuticals Bellicum is a clinical stage
biopharmaceutical company focused on discovering and developing
cellular immunotherapies for cancers and orphan inherited blood
disorders. Bellicum is using its proprietary Chemical Induction of
Dimerization (CID) technology platform to engineer and control
components of the immune system. Bellicum is developing
next-generation product candidates in some of the most important
areas of cellular immunotherapy, including hematopoietic stem cell
transplantation (HSCT), and CAR T and TCR cell therapies. More
information can be found at www.bellicum.com.
Forward-Looking Statement This press release
contains forward-looking statements for purposes of the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: , our capital needs
and uses, our intentions and abilities to continue executing on our
business plan and the upcoming readouts on our clinical programs.
Various factors may cause differences between Bellicum’s
expectations and actual results as discussed in greater detail
under the heading “Risk Factors” in Bellicum’s filings with the
Securities and Exchange Commission, including without limitation
our annual report on Form 10-K for the year ended December 31, 2017
and our report on Form 10-Q for the quarter ended March 31, 2018.
Any forward-looking statements that Bellicum makes in this press
release speak only as of the date of this press release. Bellicum
assumes no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
Source: Bellicum Pharmaceuticals
Investors:
Solebury Trout
Chad Rubin
646-378-2947
crubin@soleburytrout.com
Media:
Solebury Trout
Brad Miles
646-513-3125
bmiles@troutgroup.com
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bellicum Pharmaceuticals (NASDAQ:BLCM)
Historical Stock Chart
From Apr 2023 to Apr 2024